Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. November 2021 08:05 ET | Quelle: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
12. Oktober 2021 08:35 ET | Quelle: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
13. April 2021 08:05 ET | Quelle: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...